Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of GLPG3312 in Healthy Volunteers
NCT03800472Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Jan 2019
- Primary completion
- Mar 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GLPG3312 in Inflammatory Disorders (9 arms), sponsored by Galapagos NV. Primary endpoint: Frequency and severity of treatment emergent adverse events (TEAEs) at 9 months. Started Jan 2019; status: completed.
02
Drugs
GLPG3312
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on NCT03800472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800472.